Axonics Inc. (AXNX)
Bid | n/a |
Market Cap | 3.63B |
Revenue (ttm) | 432.08M |
Net Income (ttm) | -5.66M |
EPS (ttm) | -0.1 |
PE Ratio (ttm) | -709.8 |
Forward PE | 82.93 |
Analyst | n/a |
Ask | n/a |
Volume | 0 |
Avg. Volume (20D) | 458,235 |
Open | undefined |
Previous Close | 70.98 |
Day's Range | 70.98 - 70.98 |
52-Week Range | 55.09 - 71.05 |
Beta | 0.83 |
About AXNX
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacra...

10 months ago · https://www.defenseworld.net
Axonics, Inc. (NASDAQ:AXNX) Shares Sold by Amalgamated BankAmalgamated Bank cut its holdings in shares of Axonics, Inc. (NASDAQ:AXNX – Free Report) by 6.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities an...

10 months ago · businesswire.com
Axonics Receives Regulatory Approval for Recharge-Free SNM System in AustraliaIRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ re...